Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) EPS (Weighted Average and Diluted) (2021 - 2026)

Enliven Therapeutics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.38 for Q1 2026.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.38 for Q1 2026, up 33.33% from a year ago — trailing twelve months through Mar 2026 was -$1.67 (up 13.02% YoY), and the annual figure for FY2025 was -$1.83, up 3.17%.
  • EPS (Weighted Average and Diluted) reached -$0.38 in Q1 2026 per ELVN's latest filing, up from -$0.48 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.32 in Q3 2025 and bottomed at -$3.27 in Q3 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.49 (2025), compared with a mean of -$1.08.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 341.89% in 2022 before it soared 85.66% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$2.9 in 2022, then skyrocketed by 84.14% to -$0.46 in 2023, then decreased by 0.0% to -$0.46 in 2024, then fell by 4.35% to -$0.48 in 2025, then grew by 20.83% to -$0.38 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ELVN at -$0.38 in Q1 2026, -$0.48 in Q4 2025, and -$0.32 in Q3 2025.